June 13, 2022

SomaLogic in licensing deal with OncoHost

Original source here.

Colorado-based data-driven proteomics technology company SomaLogic (Nasdaq: SLGC) has signed a licensing agreement with precision oncology firm OncoHost.

As part of the agreement, OncoHost will license SomaLogic’s SomaScan Platform to develop proteomics tests for its PROphet diagnostic system, designed to predict patient response to immunotherapy therapies and provide strategies to overcome treatment resistance.

SomaLogic’s executive vice president of Healthcare and Diagnostics, Todd Johnson, said: “Proteomics is a powerful tool in the fight against cancer, and this agreement demonstrates the immense value of SomaScan’s assay capabilities to aid in diagnostic testing.

“We are excited to bring SomaLogic’s significant experience in utilizing proteomics to develop clinical diagnostics to this new partnership with OncoHost, enabling personalized cancer therapy.”

Israel-based OncoHost will establish a lab in North Carolina where it will use the SomaScan Assay kits to run protein measurements on patient samples and will also use the SomaScan Platform to develop its own laboratory-developed tests that will allow clinicians to make treatment decisions earlier in a patient’s disease progression and inform choices for alternative therapies.

Ofer Sharon, chief executive of privately-held OncoHost, said: “It is a pleasure to collaborate with a strong industry partner to deliver on the most pressing issue in oncology today – resistance to cancer treatment.

“SomaLogic’s expertise in proteomics adds immense value to our cutting-edge AI-based host response platform, allowing us to identify patterns that are predictive of patient response. Enabling personalized cancer treatment planning is no longer just a dream.”